Ralph B. D'Agostino, Jr. PhD
Bowdoin College, AB, Mathematics
Harvard University, AM, Statistics
Harvard University, PhD, Statistics
Dr. D'Agostino has been the Director of the Biostatistics Core since 2004. He holds a PhD in Mathematical Statistics from Harvard University and is a tenured Professor in the department of Biostatistical Sciences. Dr. D’Agostino joined the faculty at Wake Forest in 1994 and during these past 16 years he has become a leader in methodological and collaborative research in both statistical and medical areas. He has served/serves on several editorial boards and on numerous review panels for the NIH and DOD, including being a member of the NCI SPORE review panels in 2010 (Feb/Sept) and 2011 (Feb). Dr. D’Agostino has also served on more than 20 data safety monitoring committees, including many with the primary therapeutic agents targeting cancer treatments (i.e. XL184-203 A Randomized Discontinuation Study of XL184 in Subjects with Advanced Tumors and XL184-301 An International, Randomized Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer).
Observational Study Methodology
Propensity Score methods
Missing Data Methods
Measurement Error models
Colon Cancer Prevention
Dr. D’Agostino has been the PI, Co-PI, and the lead/senior statistician for numerous federally funded grants or subcontracts. Previously, Dr. D’Agostino was the PI on two NCI funded RO1’s. The first was funded to develop statistical methodology for handling missing data in epidemiological studies and the second was a coordinating center for the Insulin Resistance and Adenomas of the Colorectum project. This project is a large-scale epidemiologic study of the relationship between insulin resistance and colon cancer. In addition, he is currently funded on 7 externally funded grants as the lead statisticians that focus on cancer research (5 NCI grants, one CDC grant and one Susan G. Komen grant). He has published over 180 manuscripts and book chapters in areas of statistical methodology, cardiovascular disease, diabetes, cancer and genetics. He has extensive experience in the design and analysis of clinical trials, observational studies and large scale epidemiologic studies including the Insulin Resistance Atherosclerosis Study (IRAS), Subclinical Cardiovascular Disease Study (MESA) and the Search for Diabetes in Youth Study (SEARCH).
Recent Peer-Reviewed Publications:
Pinnix ZK, Miller LD, Wang W, D’Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010 Aug4;2(43):43ra56. PMID:20686179
Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, Jordan J, Workman S, Hundley WG. Early Detection of Doxorubicin Cardiotoxicity Using Gadolinium Enhanced Cardiovascular Magnetic Resonance Imaging. Circ Cardiovasc Imaging. 2010 Jul 9. [Epub ahead of print]PMID: 20622140
Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010 Jan 1;28(1):166-72. Epub 2009 Nov 9.PMID: 19901105
Ghosh S, Dutta S, Gomes E, Carroll D, D'Agostino R Jr, Olson J, Guthold M, Gmeiner WH. Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. ACS Nano. 2009 Sep 22;3(9):2667-73. PMID: 19655728
Burke A, Ding X, Singh R, Kraft RA, Levi-Polyachenko N, Rylander MN, Szot C, Buchanan C, Whitney J, Fisher J, Hatcher HC, D'Agostino R Jr, Kock ND, Ajayan PM, Carroll DL, Akman S, Torti FM, Torti SV. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12897-902. Epub 2009 Jul 20 PMID: 19620717
Smith AJ, Karpova Y, D'Agostino R Jr, Willingham M, Kulik G. Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One. 2009 Jul 13;4(7):e6224. PMID: 19593445
Dance-Barnes ST, Kock ND, Moore JE, Lin EY, Mosley LJ, D’Agostino RB Jr, McCoy TP, Townsend AJ, Miller MS. Lung tumor promotion by curcumin. Carcinogenesis 2009 Jun;30(6):1016-23. Epub 2009 Apr 9.PMID: 19359593
Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A. 2009 106(2):570-5. PMID: 19126685
Norris AM, Gentry M, Peehl DM, D'Agostino R Jr, Scarpinato KD. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009 18(1):57-64 PMID: 19124481
Jiao Y, Wilkinson J, Di X, Wang W, Hatcher H, Kock ND, D’Agostino R Jr, Knovich MA, Torti FM, Torti SV. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 2009 113(2):462-9. PMID: 18606936
Schwer AL, Ballonoff MD, McCammon MD, Rusthoven MD, D’Agostino RB Jr., Schefter TE. Survival effect of neoadjuvant radiotherapy before espohagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiation Oncology Biol Phys. 2009 73(2):449-55
Greven KM, White DR, Browne JD, Williams DW 3rd, McGuirt WF Sr, D’Agostino RB Jr. Swallowing dysfunction is a common sequelae after chemoradiation for oropharynx carcinoma. Am J Clin Oncol. 2008 31(3):209-212.
Dance-Barnes ST, Kock ND, Floyd HS, Moore JE, Mosley LJ, D’Agostino RB Jr, Pettanati MJ, Miller MS. Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors, Toxicol Apply Pharacol 2008 231(1):77-84.
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27(2):157-72.
Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D’Agostino RB Jr, Willingham MC, Inoue K. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell. 2007 Oct;12(4):381-94.